HUTCHMED Highlights Clinical Data for Savolitinib and Fruquintinib at 2026 ASCO Annual Meeting

HUTCHMED (China) Limited announced that new and updated clinical data for its compounds, including savolitinib and fruquintinib, will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Key presentations include results from a pivotal Phase II study of savolitinib in gastric cancer patients with MET amplification, which met its primary endpoint for objective response rate. Data supporting the New Drug Application (NDA) submission in China will be shared. Additionally, further analyses from studies involving fruquintinib in various cancer types, such as colorectal and renal cell carcinoma, will be presented. The company will also share data from investigator-initiated studies exploring fruquintinib and surufatinib across a range of potential tumor indications. These presentations underscore HUTCHMED's commitment to advancing targeted therapies and immunotherapies for cancer treatment.